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Received August 26, 2013; accepted September 5, 2013AbstractBackground: Lung involvement is one of the major systemic manifestations of primary Sjo¨gren’s syndrome (pSS). This study aims to
demonstrate the correlation between high-resolution computed tomography (HRCT), pulmonary function test (PFT) results, and outcome in
these patients.
Methods: Forty-four pSS patients were enrolled and their PFT results and HRCT findings/scores were retrospectively investigated.
Results: All patients had reduced carbon monoxide-diffusing capacity (DLCO;<75% of the predicted value);<60% of the predicted value of peak
expiratory flow (PEF), of forced vital capacity (FVC), and of forced expiratory volume in the 1st second (FEV1) were noted in 15 (34.1%) patients,
13 (29.5%) patients, and 12 (27.3%) patients, respectively. HRCT scores had a negative correlation with DLCO (r¼0.376, p¼ 0.012), but not with
other PFT results. Twelve patients (27.3%) expired during a mean follow-up of 3.7 years; 11 (91.7%) patients died of respiratory failure in the lung-
involved patients, of which three were present with pneumonia. The expired patients had lower predicted values of FEV1 (63.1  19.4% vs.
79.0  22.7%, p ¼ 0.017), FVC (58.7  20.4% vs. 77.1  17.5%, p ¼ 0.005), and PEF (54.3  20.5% vs. 72.0  24.8%, p ¼ 0.035), and higher
HRCT scores (9.2 5.7 vs. 5.2 3.5, p¼ 0.033) than those patients who survived. Patients with FEV1, FVC, PEF< 60% of the predicted value, or
high HRCT score (13e18) presented shorter median overall survival (p ¼ 0.005, p < 0.001, p ¼ 0.021, p < 0.001, respectively). Multivariate
analysis adjusted for PFT results showed that HRCT 13 was an independent risk factor for mortality (p ¼ 0.007).
Conclusion: The clinical outcome of pSS patients with lung involvement in Taiwan is not very favorable. Although HRCT score was poorly
correlated with PFT, high HRCT score was significantly associated with higher mortality.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Primary Sjo¨gren’s syndrome (pSS) is a systemic autoim-
mune disease that predominantly impairs the functioning ofThe authors declare that there are no conflicts of interest related to the subject
matter or materials discussed in this article.
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http://dx.doi.org/10.1016/j.jcma.2013.11.001the exocrine glands due to focal lymphocytic infiltration and
usually presents clinically as persistent dryness of the mouth
and eyes.1 Systemic involvement of the musculoskeletal,
cutaneous, pulmonary, gastrointestinal, renal, and/or nervous
organs/systems is present in 50e80% of pSS patients. Inter-
stitial lung disease (ILD) and small airway abnormalities are
the main pathologic findings in pSS with pulmonary
involvement.2e5 Lung involvement in particular is a very
important determinant of the patient’s clinical status, quality
of life, and outcome.hinese Medical Association. All rights reserved.
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varies, ranging from 9% to 90% in Caucasians.6,7 The reasons
for this variation remain unclear but may include underdiag-
nosis due to insignificant symptoms, ethnic, environmental, or
genetic factors, or statistical error resulting from limited
sample sizes. Chest radiographs, pulmonary function tests
(PFTs), and high-resolution computed tomography (HRCT) of
the lung are used to investigate the presence and severity of
involvement; HRCT is a relatively noninvasive method and is
currently the most important way to detect early lung paren-
chymal abnormalities and decreased lung function. HRCT has
been proven to be very sensitive for lung involvement in pa-
tients with pSS, even in patients without pulmonary symp-
toms.3,8 Common HRCT findings of pSS in the lungs include
ground-glass attenuation, bronchiectasis, a reticular pattern, or
a honeycomb appearance.9,10 The HRCT scoring method has
been used to evaluate lung diseases and is a good predictor of
patient outcome. HRCT score has only been described in 14
pSS patients with pulmonary symptoms, but its correlation
with outcome has not been previously investigated.10
The prognosis of patients with pSS is good unless organ
involvement manifests. The major causes of mortality of pSS
patients are cardiovascular diseases (32.4e52.9%) and he-
matologic malignancy (17.6e23.5%), which can be either
related or unrelated to pSS.11,12 However, the influence of lung
involvement on the outcomes of patients with pSS have yet to
be well elucidated. Ito et al9 analyzed PFT and HRCT in 33
pSS patients, and found that low partial oxygen pressures and
the presence of honeycombing were related to higher mor-
tality. The aim of this study was to determine the clinical
characteristics of lung involvement in Taiwanese patients with
pSS. Their PFT results, HRCT findings, HRCT scores, and
causes of death were recorded. Risk factors for mortality in
pSS patients were also investigated.
2. Methods2.1. PatientsThe Taipei Veterans’ General Hospital (Taipei, Taiwan) is a
3000-bed acute care hospital that serves as a tertiary referral
center. Patients treated at this hospital with a diagnostic code for
pSS (ICD-9 710.2) between January 1996 and December 2009
were recruited for this study. All patients satisfied the 2002
AmericaneEuropean Revised Classification Criteria for pSS.13
To arrive at a definitive diagnosis, it is essential to meet: (1) at
least four of six criteria, of which criteria IVand VI are positive;
or (2) at least three of the IIIeVI criteria. The criteria are: (I)
ocular symptoms of decreased tear production; (II) oral symp-
toms of decreased saliva production; (III) objective evidence of
ocular involvement, Schirmer’s test 5 mm/5 minutes, or rose
bengal score 4; (IV) salivary gland histopathology with lym-
phocytes focus score 1; (V) objective evidence of salivary
gland involvement (either unstimulated whole salivary flow
<1.5 mL in 15 minutes, diffuse sialectasis by parotid sialog-
raphy, or salivary scintigraphy showing delayed uptake); and
(VI) presence of autoantibodies (anti-SSA/Ro, anti-SSB/La, orboth). In addition, these illnesses mimicking SS, such as past
history of head and neck irradiation treatment or pre-existing
lymphoma, hepatitis B or C infection, acquired immunodefi-
ciency disease, sarcoidosis, or graft versus host disease, should
be excluded. Patients with other connective tissue diseases that
could have induced secondary SS, such as systemic lupus ery-
thematosus, rheumatoid arthritis, polymyositis, dermatomyo-
sitis, scleroderma, primary biliary cirrhosis, and mixed
connective tissue disease, were excluded.14
The clinical and immunological profiles, PFT results, and
HRCT findings of all patients were analyzed. Forty-four pSS
patients were diagnosed as having coexisting lung involvement,
defined as the persistence of pulmonary symptoms, such as
dyspnea or cough, with coexisting abnormal PFT and/or HRCT
findings for longer than 2weeks.4,15 Other medical illnesses that
could cause pulmonary manifestations, such as chronic heart
failure, infection, hyperthyroidism, arrhythmia, and bronchial
asthma, were excluded by clinical assessment and other labo-
ratory investigations, including echocardiographic studies,
electrocardiography, and thyroid function tests.
This study was approved by the institutional ethics com-
mittee of Taipei Veterans’ General Hospital, Taiwan (2013-03-
028BC).2.2. PFT and radiologic analysisRoutinely evaluated PFT included forced expiratory vol-
ume in the first second (FEV1), forced vital capacity (FVC),
carbon monoxide-diffusing capacity (DLCO), residual volume
(RV), and peak expiratory flow (PEF). All HRCT examina-
tions were performed using contiguous axial 5 mm section
thickness through the lungs on a Toshiba Aquilion 64 CT
scanner (Toshiba, Tokyo, Japan). HRCT findings were read by
experienced chest radiologists and categorized according to
the classification of CT patterns described by the American
Thoracic Society/European Respiratory Society International
Multidisciplinary Consensus Classification of the Idiopathic
Interstitial Pneumonias.16 HRCT scoring was performed ac-
cording to the definitions reported previously by Schurawitzki
et al.17 Briefly, each of the six lobes of the lung with the
lingula counted as a separate lobe was assessed based on the
percentage of affected lung parenchyma. Grades were defined
as follows: Grade 0, no involvement; Grade 1, involvement up
to 25% of a lobe; Grade 2, involvement between 26% and 50%
of a lobe; and Grade 3, involvement >50% of a lobe. The
HRCT score was obtained by combining grades over all six
“lobes”, with a possible range of 0e18. The severity of lung
involvement was classified according to the HRCT, where 0e6
was defined as mild, 7e12 was defined as moderate, and
13e18 was defined as severe.102.3. Statistical analysisThe goodness-of-fit test, Chi-square test, and/or Fisher’s
exact test were used to compare categorical variables. Spearman
rank correlations were calculated between HRCT scores and
PFT values. Overall survival rate was estimated using the
77M.-H. Chen et al. / Journal of the Chinese Medical Association 77 (2014) 75e82KaplaneMeier method, and survival curves were compared
using the log-rank test. A p value <0.05 was considered statis-
tically significant. Statistical analyses were performed using
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
3. Results3.1. Clinical features and PFT results of patients with
pSS with lung involvementTable 2
Results of HRCT scores and PFTs in 44 pSS patients with lung involvement.
No. Age (y) Sex HRCT
score
FEV1 FVC DLCO FEV1/
FVC
RV PEF
Survived
1 50 F 1 83 87 64 95 74 87
2 37 F 1 83 85 54 98 72 60
3 78 M 1 113 117 69 97 97 65
4 69 F 1 74 80 57 93 112 88
5 72 M 1 23 52 33 44 272 35
6 82 M 1 106 97 74 109 93 86
7 84 F 1 54 49 42 110 79 16
8 43 F 2 72 68 42 106 96 72
9 45 F 2 71 64 58 111 98 64
10 58 F 2 38 87 60 44 129 21
11 68 F 3 76 78 53 97 100 46
12 73 F 3 83 84 40 99 86 73Among our 44 pSS patients with lung involvement (17 male
and 27 female), the mean age at diagnosis was 66.5 years (Table
1). Twelve patients, all of whom were male, had a history of
smoking. An antinuclear antibody (ANA) titer of >1:160 was
noted in 63.6% of all patients and rheumatoid factor (RF) was
positive in 11 of 40 (27.5%) patients. As shown inTables 1 and 2,
PFTwas performed and HRCT scans were obtained from all 44
patients with lung involvement. All patients (44 of 44, 100%)
showed restrictive-type results with reduced DLCO (<75% of
the predicted value). In addition, 15 (34.1%) patients had PEF
results <60% of the predicted value, 13 (29.5%) patients had a
reduced FVC, 12 (27.3%) individuals had a reduced FEV1, four
(9.3%) individuals had a reduced RV, and only one (2.3%) pa-
tient had a reduced FEV1/FVC (<60% of the predicted value).13 77 F 4 99 74 44 134 131 61
14 22 F 5 43 41 45 105 100 58
15 71 F 5 84 78 35 108 61 74
3.2. HRCT findings16 62 F 6 61 55 35 111 76 74
17 68 M 6 95 81 29 117 77 126
18 75 M 6 96 97 49 99 64 70
19 78 F 6 64 63 21 102 65 48
20 76 M 7 53 64 56 83 133 61
21 34 F 7 106 97 51 109 72 77
22 76 F 7 99 79 35 125 43 109
23 80 M 8 99 81 50 122 82 104
24 65 M 8 88 100 31 88 78 71
25 67 M 8 67 59 41 114 83 58
26 59 F 8 101 96 52 105 144 118
27 68 F 8 74 71 49 104 107 90
28 62 F 9 64 71 38 90 100 76
29 83 M 10 111 95 63 117 81 80The HRCT features are summarized in Table 3, and some
patterns are shown in Fig. 1. All scans showed a mixed pattern.
The most frequent HRCT finding was interstitial linear
opacities (88.6%), followed by interlobular septal thickening
(81.8%), and ground-glass opacities (77.3%). The distribution
of parenchymal lung involvement was uneven, and was found
to be most pronounced in the lower lobes (upper; middle; and
lower lobes ¼ 28.6%; 33.3%; and 38.1%, respectively).
Analysis of the HRCT scores showed that 20 (45.5%) patients
had mild, 17 (38.6%) patients had moderate, and 7 (15.9%)
patients had severe lung involvement.Table 1
Demographic, immunologic profiles, and PFTs in 44 pSS patients with lung
involvement.
N
Age at diagnosis (y) 66.5  14.8
Male:female 17:27
Smoker 12 (27.3)
ANA > 1:160 28/44 (63.6)
Rheumatoid factor (þ) 11/40 (27.5)
DLCO < 75% of the predictive value 44/44 (100.0)
PEF < 60% of the predictive value 15/44 (34.1)
FEV1 < 60% of the predictive value 12/44 (27.3)
FVC < 60% of the predictive value 13 (29.5)
FEV1/FVC < 60% of the predictive value 1 (2.3)
RV < 60% of the predictive value 4/43 (9.3)
Data are presented as n (%), n/N (%), or mean  SD.
ANA ¼ antinuclear antibody; DLCO ¼ carbon monoxide-diffusing capacity;
FEV1 ¼ forced expiratory volume in the first second; FVC ¼ forced vital
capacity; PEF ¼ peak expiratory flow; PFT ¼ pulmonary function test;
pSS ¼ primary Sjo¨gren’s syndrome; RV ¼ residual volume.3.3. Correlation between HRCT score and PFT resultsAs shown in Fig. 2, investigation of the association between
total HRCT scores and PFT results revealed a negative cor-
relation between HRCT scores and DLCO (r ¼ 0.376,
p ¼ 0.012), but no correlation between HRCT scores and
FEV1 (r ¼ 0.031, p ¼ 0.842), FVC (r ¼ 0.142, p ¼ 0.357),30 78 F 10 83 75 33 111 76 58
31 81 M 11 107 88 56 122 77 104
32 70 M 13 87 79 34 110 91 74
Expired
1 67 F 1 66 63 56 105 154 31
2 40 F 1 78 83 46 94 84 84
3 73 F 3 53 47 26 113 NA 36
4 80 M 5 60 45 4 133 90 46
5 74 M 7 49 39 57 126 37 61
6 62 F 9 57 57 33 100 26 46
7 84 M 13 55 57 53 96 95 46
8 73 F 13 99 102 44 97 84 82
9 74 M 13 43 39 31 110 67 38
10 60 F 13 52 51 20 102 111 31
11 47 F 14 45 39 32 115 44 85
12 79 M 18 100 82 36 122 63 65
Data are presented as %, unless otherwise indicated.
DLCO ¼ carbon monoxide-diffusing capacity; F ¼ female; FEV1 ¼ forced
expiratory volume in the first second; FVC ¼ forced vital capacity;
HRCT ¼ high-resolution computed tomography; M ¼ male; NA ¼ not
available; PEF ¼ peak expiratory flow; PFT ¼ pulmonary function test;
pSS ¼ primary Sjo¨gren’s syndrome; RV ¼ residual volume.
Table 3
HRCT features in 44 pSS patients with lung involvement.
HRCT findings N (%)
Interstitial linear opacities 39 (88.6)
Interlobular septal thickening 36 (81.8)
Ground-glass opacities 34 (77.3)
Cysts 32 (72.7)
Bronchiectasis 31 (70.5)
Reticular pattern 31 (70.5)
Honeycombing 29 (65.9)
Mediastinal lymph node enlargement 25 (56.8)
Nodular opacities 23 (52.3)
Airspace consolidation 20 (45.5)
HRCT ¼ high-resolution computed tomography; pSS ¼ primary Sjo¨g-
ren’s syndrome.
Fig. 2. Spearman’s correlation between high-resolution computed tomography
(HRCT) scores and pulmonary function tests (PFTs) of % of predicted value
for carbon monoxide-diffusing capacity (DLCO) in primary Sjo¨gren’s syn-
drome (pSS) patients with lung involvement. *Significant p value.
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p ¼ 0.091), or PEF (r ¼ 0.138, p ¼ 0.373).3.4. Outcome analysisTwelve (27.3%) of the 44 patients died during the follow-
up period (mean follow-up time, 3.73 years; range, from 2
months to 16 years). The causes of death among the patients
with pSS in this study included respiratory failure (n ¼ 8,
66.7%), pneumonia with respiratory failure (n ¼ 3, 25.0%),
and sepsis (n ¼ 1, 8.3%). PFT and HRCT scores were
compared between those of the 44 patients with lung
involvement who died during follow-up and those who sur-
vived (Table 4). Patients who died during follow-up had lower
predicted values for FEV1 (63.1  19.4% vs. 79.0  22.7%,
p ¼ 0.017), FVC (58.7  20.4% vs. 77.1  17.5%, p ¼ 0.005),
and PEF (54.3  20.5% vs. 72.0  24.8%, p ¼ 0.035) as well
as higher HRCT scores (9.2  5.7 vs. 5.2  3.5, p ¼ 0.033)
than those who survived. There was no significant differenceFig. 1. High-resolution computed tomography (HRCT) scan showing interstitial lin
pattern (arrow) and honeycombing appearance (arrowhead) (C), and airspace consbetween deceased and surviving patients for other PFT results
and clinical profiles, including predicted values for DLCO,
FEV1/FVC, RV, age at diagnosis, sex, smoking history, posi-
tive ANA (>1:160), and positive RF (all p > 0.05).
KaplaneMeier survival analysis showed that median
overall survival was shorter among patients whose FEV1 value
was <60% of the predicted value than those whose FEV1
value was >60% of the predicted value (p ¼ 0.005; Fig. 3A).
Patients with reduced FVC values (<60% of the predicted
value) had shorter median overall survival than those with
FVC values >60% of the predicted value (p < 0.001; Fig. 3B).
Similarly, patients with reduced PEF values (<60% of the
predicted value) had shorter median overall survival than those
with PEF values >60% of the predicted value (p ¼ 0.021;
Fig. 3C). Furthermore, patients with severe lung involvement
(high HRCT scores of 13e18) had shorter median overallear opacities (arrow) (A), interlobular septal thickening (arrow) (B), reticular
olidation (arrow) (D).
Table 4
Comparison of clinical profile, PFT results, and HRCT scores between expired
and survival groups in 44 pSS patients with lung involvement.
Expired
N ¼ 12
Survived
N ¼ 32
p
Age at diagnosis (y) 67.8  13.4 66.0  15.5 0.805
Male 5/12 (41.7) 12/32 (37.5) 1.000
Smoker 4/12 (33.3) 8/32 (25.0) 0.707
ANA > 1:160 8/12 (66.7) 20/32 (62.5) 1.000
Rheumatoid factor (þ) 3/10 (30.0) 8/30 (26.7) 1.000
FEV1 (% of the predictive value) 63.1  19.4 79.0  22.7 0.017*
FVC (% of the predictive value) 58.7  20.4 77.1  17.5 0.005*
DLCO (% of the predictive value) 36.5  15.7 46.7  12.6 0.063
FEV1/FVC (% of the predictive value) 107.5  10.7 101.6  18.5 0.442
RV (% of the predictive value) 77.7  36.4 95.3  39.3 0.230
PEF (% of the predictive value) 54.3  20.5 72.0  24.8 0.035*
HRCT scores 9.2  5.7 5.2  3.5 0.033*
Data are presented as n (%) or mean  SD.
*A p value<0.05 was considered significant.
ANA ¼ antinuclear antibody; DLCO ¼ carbon monoxide diffusing capacity;
FEV1 ¼ forced expiratory volume in the first second; FVC ¼ forced vital
capacity; HRCT ¼ high-resolution computed tomography; PEF ¼ peak
expiratory flow; pSS ¼ primary.
Fig. 3. KaplaneMeier survival curves of primary Sjo¨gren’s syndrome (pSS) pati
expiratory volume in the first second (FEV1)  and <60% of the predicted value;
79M.-H. Chen et al. / Journal of the Chinese Medical Association 77 (2014) 75e82survival than those with mild or moderate lung involvement
(HRCT scores of 0e12; p < 0.001; Fig. 3D). Multivariate
analysis adjusted for FEV1, FVC, and PEF, showed that severe
lung involvement (HRCT score 13e18) was an independent
risk factor for mortality in patients with lung involvement
(p ¼ 0.007, odds ratio ¼ 40.154, 95% CI ¼ 2.747e586.991).
In addition, being aged > 65 years, sex, and smoking history
were not major predictors of mortality in pSS patients with
lung involvement.4. Discussion
The clinical course of patients with pSS is usually confined to
the sicca symptoms unless the extraglandular organs are
involved. This study analyzed the clinical characteristics, HRCT
findings, and PFT results in pSS patients with lung involvement
in Taiwan. Several studies have reported PFT and HRCT find-
ings in pSS patients as summarized in Table 5.4,8,9,13,18,19 Such
HRCT findings in pSS included ground-glass opacities, inter-
stitial linear opacities, interlobular septal thickening, nodules,ents with lung involvement. Cumulative overall survival between (A) forced
(B) forced vital capacity (FVC)  and <60% of the predicted value; (C) peak
Table 5
Summary of HRCT studies in patients with pSS.a
Study (Ref) Year Patients Race HRCT
score
(N)
Major HRCT findings PFT Conclusions
Franquet et al3 1997 50 (13 with pulmonary
symptom)
Spain NA 1. Bronchiolar abnormalities and
parenchymal lines (22.0%)
2. Ground-glass opacities (14.0%)
3. Bronchiolectasis (12.0%)
4. Rounded areas of attenuation (10.0%)
NA 1. HRCT was a sensitive technique
in assessing lung involvement of pSS
2. ILD and bronchiolar inflammatory
changes were common abnormal findings
Koyama et al18 2001 60 (not specified) Japan NA 1. Ground-glass opacities (91.7%)
2. Subpleural small nodules (78.3%)
3. Non-septal linear opacities (75.0%)
4. Interlobular septal thickening (55.0%)
NA 1. The most common HRCT finding
was ground-glass attenuation
Ito et al9 2005 33 (not specified, 31
received HRCT
examination)
Japan
Korea
NA 1. Nonspecific interstitial pneumonia
pattern (54.8%)
2. Usual interstitial pneumonia pattern
(12.9%)
3. Bronchiolitis (12.9%)
4. Cysts (9.7%)
1. Restrictive changes (< 80%
of predicted VC): 58%
2. Obstructive changes (< 70 f
predicted FEV1/FVC): 9%
1. Low PaO2 and presence of
microscopic honeycombing were
independently associated with survival
Watanabe et al19 2010 56 (11 with pulmonary
symptom)
Japan NA 1. Intralobular septal thickening (67.9%)
2. Cysts (39.3%)
3. Ground-glass opacities (35.7%)
4. Ill-defined centrilobular nodule (35.7%)
5. Intralobular reticular opacities (35.7%)
6. Pleural thickness (35.7%)
NA 1. Cysts were significantly associated
with the presence of anti-SSB/La and
clonally derived lymphoproliferative
disorder
Shi et al4 2009 14 (all with pulmonary
fibrosis, interstitial
pneumonia, or
suspected ILD)
China NA 1. Irregular reticular opacities (57.1%)
2. Ground-glass opacities (50.0%)
3. Interlobular septal thickening (50.0%)
4. Air space consolidation (21.4%)
1. Patients with ILD had
a restrictive defect
2. Patients with SAD had an
obstructive defect
1. ILD and SAD were the most
common respiratory forms of lung
involvement in pSS
Yazisiz et al10 2010 30 (all with pulmonary
symptom)
Turkey Yes (14) 1. Ground-glass opacities (30%)
2. Bronchiectasis (23.3%)
3. Reticular opacities (23.3%)
4. Enlarged mediastinal lymph nodes
(23.3%)
Patients with lung involvemen
had lower predicted values of
and FEV1 than those without
1. Negative correlations between
HRCT score and PFT results of FVC,
FEV1, and PEF values (<80% of
predicted value)
2. Positive correlation between HRCT
score and the pulmonary artery dilatation
Chen et al
(current study)
44 (all with pulmonary
symptom)
Taiwan 44 1. Interstitial linear opacities (88.6%)
2. Interlobular septal thickening (81.8%)
3. Ground-glass opacities (77.3%)
4. Cysts (72.7%)
1. <75% of the predicted
DLCO: 100.0%
2. <60% of the predicted
PEF: 34.1%
3. <60% of the predicted
FVC: 29.5%
4. <60% of the predicted
FEV1: 27.3%
1. A negative correlation between
HRCT scores and DLCO
2. Patients with FEV1, FVC, PEF
<60% of the predicted value, or high
HRCT score (13-18) presented shorter
median overall survival
3. HRCT score 13 was an independent
risk factor for mortality
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findings are varied; for example, ground-glass opacities range
from 10.8% to 91.7%, interlobular septal thickening range from
24.3% to 55.0%, nodules range from 24.3% to 78.3%, and cysts
range from 9.7% to 39.3%. However, the ground-glass opacities
pattern seems to be seen less frequently in patients without
pulmonary symptom, suggesting that less severe lung involve-
ment goes hand-in-hand with low prevalence of ground-glass
opacities. All of our patients presented with lung involvement;
the most frequent HRCT findings were interstitial linear opac-
ities (88.6%), interlobular septal thickening (81.8%), ground-
glass opacities (77.3%), and cysts (72.7%). The discrepancy
of the above results could be partially explained by a difference
in race, sex distribution, duration of disease, age at examination,
and severity of lung injury.
PFT in pSS can be restrictive or obstructive, even in patients
without pulmonary symptoms.4,8 All of our pSS patients, having
been presentedwith lung involvement, had lowDLCO (<75% of
predicted vital capacity value), whereas <50% had decreased
FEV1 and FVC (<60% of predicted vital capacity value). As
shown in Table 5, Shi and colleagues4 reported that PFT results
of pSS patients with ILD had a restrictive pattern. Another study
determining the PFT results of 33 pSS patients found that over
half had restrictive change (<80% of predicted vital capacity
value).9 An obstructive defect of PFT was mainly observed in
pSS patients with small airway disease.2,4 Compared to these
studies, restrictive change was noted in only 8.1% of pSS pa-
tients without pulmonary symptoms in the Uffmann et al8 study,
indicating that more serious restrictive-type impairment was
noted in pulmonary function of patients with lung involvement
than in patients without lung involvement. A limited number of
studies focusing on the relationship between HRCT score and
PFT have been conducted. Our current study revealed that
impairment of DLCO was associated with high HRCT scores.
This finding was similar to the report by Yazisiz et al,10 in which
negative correlations between HRCT scores and PFT results
were found in 14 Turkish pSS patients with lung involvement.
Taking these findings together, we postulated that higher HRCT
score is related to more severe lung impairment.
Previous studies have reported that the standardized mor-
tality ratio of patients with pSS is slightly higher than that of
age- and sex-matched populations, ranging from 1.17 to
2.07.11,12,20,21 A prospective cohort study comprising 484
Swedish patients with pSS with a median follow-up time of 7
years showed that the all-cause mortality was no higher in
patients with pSS than in the general population.12 The exact
relationship between pulmonary involvement and mortality
rate among pSS patients remains to be explored, and more
studies should be conducted to further elucidate the connec-
tion. Some reports have suggested that pulmonary manifesta-
tions of pSS do not worsen the prognosis. A 10-year follow-up
of 30 British patients with pSS reported by Davidson et al22
found that most patents had stable pulmonary function, and
mortality was low (15.4%). The mortality rate of our Taiwa-
nese pSS patients with lung involvement was 27.3%, similar to
the observation of Ito et al9; in their analysis of 33 Japanese
and Korean pSS patients with lung involvement, 10 (30.3%)
82 M.-H. Chen et al. / Journal of the Chinese Medical Association 77 (2014) 75e82expired. In the study by Davidson et al,22 four (15.4%) of 26
British patients with pSS died during the 10-year follow-up
period: one patient died of respiratory disease (fibrosing
alveolitis complicated by bronchopneumonia) and three pa-
tients died of cerebrovascular events and cancer.22 In our
study, the most common cause of death was respiratory failure
(11 of 12 patients, 91.7%) with or without coexisting pneu-
monia (n ¼ 3). Taken together, the outcome of pSS with lung
involvement in an Asian population seems to be unfavorable.
In addition to exploring the relationship between HRCT
score and PFT, our current study demonstrated that the mor-
tality rate was higher in patients with high HRCT scores than
those with low HRCT scores in pSS patients with lung
involvement. This is the first study to show HRCT to be a good
predictor of survival in patients with pSS with lung involve-
ment. A previous study suggested that the presence of
microscopic honeycombing was independently associated
with mortality.9 The percentage of patients in our study whose
HRCT scans showed a honeycomb pattern was 65.9%, higher
than reported in other studies (range, 23.5e42.8%).3,10 This
may explain why the mortality rate of our patients was higher
than other previous reports. Even patients with low FEV1,
FVC, or PEF presented shorter median overall survival;
multivariate analysis adjusted for these PFT results showed
that high HRCT score was an independent risk factor for
mortality, suggesting that HRCT findings can better reflect the
severity of lung involvement in patients with pSS.
There are some limitations in this study. First, patients
without pulmonary symptoms were not included. Second, this
is not a prospective study. Furthermore, another limitation was
the small sample size.
In conclusion, the presence of lung involvement with a high
HRCT score or poor PFTwas determined to be a risk factor for
mortality in patients with pSS in Taiwan.
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